Signed in · PRO

Guidance history, every release

BioMarin Pharmaceutical (BMRN) · 8 releases, Oct 29, 2024 to Aug 6, 2026 · rows are metrics, columns are releases

Raised · a change from the previous releaseSame · restated unchanged— · not stated in that releaseEvery value links to its sentence in the filing

Metric	Oct 29, 2024 FY24 Q3	Feb 19, 2025 FY24 Q4	May 1, 2025 FY25 Q1	Aug 4, 2025 FY25 Q2	Oct 7, 2025 FY25 Q3	Jan 12, 2026 FY25 Q4	May 4, 2026 FY26 Q1	Aug 6, 2026 FY26 Q2
For FY2034
Total revenues CAGR	New“Mid-teen compound annual growth rate (CAGR)”	—	—	—	—	—	—	—
Total revenues compound annual growth rate (CAGR)	New“Mid-teen”	—	—	—	—	—	—	—
For FY2030
Peak revenue for GALAFOLD	—	—	—	—	—	—	—	New“approximately $1.4 billion”
Peak revenue for POMBILITI + OPFOLDA	—	—	—	—	—	—	—	New“approximately $1.2 billion”
GALAFOLD and POMBILITI + OPFOLDA, combined, Non-GAAP Operating Margin	—	—	—	—	—	—	—	New“over 60%”
BMN 333 achondroplasia approval target	—	—	New“2030”	—	—	—	—	—
For FY2028
Cost reductions from Amicus acquisition (GAAP basis)	—	—	—	—	—	—	—	New“approximately $280 million”
Cost reductions from Amicus acquisition (Non-GAAP basis)	—	—	—	—	—	—	—	New“approximately $220 million”
Cost reductions on a GAAP basis	—	—	—	—	—	—	—	New“approximately $280 million”
For FY2027
Total Revenues	New“Approximately $4 billion”	Reiterated“approximately $4 billion”	—	—	—	—	—	—
Gross leverage target	—	—	—	—	—	—	—	New“below 2.5 times”
Operating cash flow	New“More than $1.25 billion”	—	—	—	—	—	—	—
Operating cash flows	—	New“more than $1.25 billion”	—	—	—	—	—	—
VOXZOGO country access expansion	New“more than 20 additional countries”	—	—	—	—	—	—	—
VOXZOGO country access target	—	—	—	New“more than 60 countries”	—	—	—	—
VOXZOGO country availability	—	New“more than 60 countries”	—	—	—	—	—	—
For FY2026
Metabolic Conditions Revenue	—	—	—	—	—	—	—	New“Unchanged”
Other Revenues	—	—	—	—	—	—	New“$100 to $125”	Reiterated“$100 to $125”
PALYNZIQ Revenue	—	—	—	—	—	—	New“expected to increase year-over-year”	—
ROCTAVIAN revenue treatment in 2026	—	—	—	—	—	New“ROCTAVIAN revenue to be excluded from 2026 guidance”	—	—
Total Revenues	—	—	—	—	—	—	New“$3,825 to $3,925”	Narrowed“$3,875 to $3,925”
Total Revenues (Full-Year)	—	—	—	—	—	—	New“between $3.825 billion and $3.925 billion”	—
Total Revenues Expected in Second Half of 2026	—	—	—	—	—	—	New“more than 55%”	—
Total Revenues Growth Rate (Y/Y, at Midpoint)	—	—	—	—	—	—	New“20%”	—
Total Revenues Midpoint Growth (Y/Y)	—	—	—	—	—	—	—	New“21%”
VOXZOGO full-year 2026 revenue (CEO quote)	—	—	—	—	—	—	—	New“at least $1 billion”
VOXZOGO Revenue	—	—	—	—	—	—	—	New“$1,000 to $1,050”
Amicus Acquisition Impact on Non-GAAP Diluted EPS	—	—	—	—	—	—	New“slightly dilutive”	—
Combined company tax rate assumption for Non-GAAP Diluted EPS	—	—	—	—	—	—	—	New“22%”
Non-GAAP Diluted EPS	—	—	—	—	—	—	New“$4.85 to $5.05”	Raised“$4.90 to $5.10”
Non-GAAP Diluted EPS - combined company tax rate assumption	—	—	—	—	—	—	New“22%”	—
Non-GAAP Diluted EPS - Weighted-Average Diluted Shares Outstanding assumption	—	—	—	—	—	—	New“approximately 200 million”	—
Non-GAAP Diluted EPS (Q2 vs Q1)	—	—	—	—	—	—	New“modestly higher than in Q1”	—
Non-GAAP Diluted EPS Midpoint Growth (Y/Y)	—	—	—	—	—	—	—	New“59%”
Non-GAAP Diluted EPS Recognized in Second Half of 2026	—	—	—	—	—	—	New“approximately two-thirds”	—
Non-GAAP Operating Margin	New“40%”	Reiterated“40%”	—	—	—	—	—	—
Weighted-Average Diluted Shares Outstanding assumption for Non-GAAP Diluted EPS	—	—	—	—	—	—	—	New“approximately 200 million”
Enzyme Therapies	—	—	—	—	—	—	New“$2,725 to $2,775”	—
Metabolic Conditions	—	—	—	—	—	—	—	New“$2,725 to $2,775”
Metabolic Conditions Midpoint Growth (Y/Y)	—	—	—	—	—	—	—	New“31%”
VOXZOGO	—	—	—	—	—	—	New“$975 to $1,025”	—
VOXZOGO Midpoint Growth (Y/Y)	—	—	—	—	—	—	—	New“11%”
For FY2025
Revenue ( from Q3'25 Earnings)	—	—	—	—	—	New“$3,150M - $3,200M”	—	—
Revenue (Today's Update)	—	—	—	—	—	New“~$3.2B”	—	—
Revenue and profitability growth	—	New“Double-Digit”	—	—	—	—	—	—
Total Enzyme Therapies revenues	—	—	—	New“expected to remain robust”	—	—	—	—
Total Revenues	—	New“$3,100 to $3,200”	Reiterated“$3,100 to $3,200”	Narrowed“$3,125 to $3,200”	—	—	—	—
VOXZOGO contribution to full-year 2025 Total Revenues	—	New“$900 million to $950 million”	Reiterated“$900 million to $950 million”	Narrowed“$900 million to $935 million”	—	—	—	—
VOXZOGO revenue	—	—	—	New“expected to drive higher VOXZOGO revenue in the second half of 2025 compared to the first half of 2025, and weighted to Q4”	—	—	—	—
VOXZOGO Revenue ( from Q3'25 Earnings)	—	—	—	—	—	New“$900M - $935M”	—	—
VOXZOGO Revenue (Today's Update)	—	—	—	—	—	New“~$920M”	—	—
Charge to GAAP Diluted earnings per share (EPS)	—	—	—	—	New“approximately $1.10”	—	—	—
Non-GAAP Diluted EPS	—	New“$4.20 to $4.40”	Reiterated“$4.20 to $4.40”	Raised“$4.40 to $4.55”	—	—	—	—
Non-GAAP Diluted EPS assumed Weighted-Average Diluted Shares Outstanding	—	—	New“approximately 200 million”	Reiterated“approximately 200 million”	—	—	—	—
Non-GAAP Diluted EPS impact from acquired IPR&D charges	—	—	—	—	New“approximately $1.10”	—	—	—
Non-GAAP Operating Margin %	—	New“32% to 33%”	Reiterated“32% to 33%”	Raised“33% to 34%”	—	—	—	—
Non-GAAP Operating Margin growth	—	New“14% (3.9 percentage points) Y/Y at the mid-point of guidance”	—	—	—	—	—	—
ROCTAVIAN Asset Write Down (Non-GAAP Diluted EPS Impact) (Today's Update)	—	—	—	—	—	New“($0.60) – ($0.64)”	—	—
Roctavian asset write-down related to inventory expected to reduce Non-GAAP Diluted EPS	—	—	—	—	—	New“approximately $120M – $125M, or ($0.60) – ($0.64) per share”	—	—
Weighted-Average Diluted Shares Outstanding (EPS assumption)	—	New“approximately 200 million”	—	—	—	—	—	—
Acquired IPR&D charges (pre-tax)	—	—	—	—	New“approximately $221 million”	—	—	—
Operating expenses	—	—	—	New“expected to increase in the second half of 2025 vs. the first half of 2025”	—	—	—	—
ROCTAVIAN asset write-downs (total, incl. inventory, facilities, intangible assets, severance costs)	—	—	—	—	—	New“$230M – $260M”	—	—
For FY2024
Total Revenues	New“$2,790 to $2,825”	—	—	—	—	—	—	—
Non-GAAP Diluted EPS	New“$3.25 to $3.35”	—	—	—	—	—	—	—
Non-GAAP Operating Margin %	New“26.5% to 27.5%”	—	—	—	—	—	—	—
Cost transformation program size	—	New“$500 million”	—	—	—	—	—	—
Weighted-Average Diluted Shares Outstanding assumption	New“approximately 200 million”	—	—	—	—	—	—	—
For FY2023
VOXZOGO Revenue CAGR	—	New“exceeding 25%”	—	—	—	—	—	—
No period stated
Treatments for Skeletal Conditions revenue opportunity	New“greater than $5 billion”	—	—	—	—	—	—	—
Non-GAAP Operating Margin	New“low- to mid-40% range”	—	—	—	—	—	—	—
Enzyme Therapies long-term growth outlook (CAGR)	—	New“high single-digit CAGR”	—	—	—	—	—	—
Interest expense associated with the financing	—	—	—	—	—	—	—	New“approximately $200 million on an annualized basis”
Interest expense related to Amicus financing (annualized)	—	—	—	—	—	—	—	New“approximately $200 million”

Values in quotation marks are the company’s words. Change labels compare each statement with the same metric and target year in the previous release. HighGravityData does not judge whether guidance was met.